3D Medicines, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
No of Months
12
12
12
12
12
12
Profit Before Tax
-216.00
-621.00
-1,223.00
-1,761.00
-713.00
-363.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-49.00
122.00
-8.00
-47.00
24.00
39.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
-216.00
-154.00
-318.00
-449.00
-330.00
-281.00
Cash Flow from Investing Activities
7.00
-192.00
-289.00
-132.00
-18.00
15.00
Cash Flow from Financing Activities
-36.00
315.00
477.00
1,014.00
702.00
326.00
Net Cash Inflow / Outflow
-240.00
-33.00
-90.00
426.00
346.00
61.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
4.00
-3.00
40.00
-4.00
-7.00
1.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in HKD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of 3D Medicines, Inc.
Figures in Million
consolidated Cash Flow Results
Change(HKD)
Change(%)
Profit Before Tax
-216.170381270847
-983.849140770664
767.00
78.03%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-49.260626060346
-4.25765012230716
-45.00
-1056.99%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
-216.581302107156
-518.558835681885
302.00
58.23%
Cash Flow from Investing Activities
7.73160022089904
-1758.59169387777
1,765.00
100.44%
Cash Flow from Financing Activities
-36.7757885139075
2417.08346410736
-2,453.00
-101.52%
Net Cash Inflow / Outflow
-240.864663507728
116.391699857736
-356.00
-306.94%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
4.76082689243692
-23.5412346899721
27.00
120.22%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is -40.58% vs 51.59% in Dec 2023
Dec'24
Dec'23
Change(%)
Cash Flow from Operating Activities
-216.58
-154.06
-40.58%






